Date: 26 April 2018

Location: London (UK)

Biosimilar medicines are an essential part of healthcare provision in Europe today. Europe will continue to play a leading role in shaping a sustainable regulatory framework regionally and globally to promote greater access to essential therapies for auto-immune diseases and cancer. The Biosimilar Medicines Group has pioneered this development and supports greater global cooperation for future development.

It was a great opportunity as WFIP was asked to wrap up and close the conferences with closing remarks.